576 / 1851
Conclusion
• Biological basis for combining RT with check-point inhibitors
• In mice models there seems to be synergy
• Different toxicity profile
• Apparently not synergy re. side effects
• Trials are ongoing
• No immuno-RT treatments can be considered standard –
everything should be done in controlled trials